TY - JOUR
T1 - Fulminant liver disease
AU - Schiødt, Frank Vinholt
AU - Lee, William M.
N1 - Funding Information:
Funding: NIH grants: RO3 DK52827, RO1 DK 58369 FDA grant: FD-R-001661 Danish Medical Research Council 22-01-0125 (to Dr. FVS)
PY - 2003/6
Y1 - 2003/6
N2 - Fulminant liver disease, acute liver failure (ALF), is one of the most intriguing and challenging conditions in the entire field of internal medicine. ALF is defined as the onset of hepatic encephalopathy and coagulopathy in patients with no known underlying liver disease within 8 to 26 weeks of onset of illness. Many cases develop within a few days, dramatically transforming an otherwise healthy individual to a patient with a high risk for developing multi-organ failure and death.
AB - Fulminant liver disease, acute liver failure (ALF), is one of the most intriguing and challenging conditions in the entire field of internal medicine. ALF is defined as the onset of hepatic encephalopathy and coagulopathy in patients with no known underlying liver disease within 8 to 26 weeks of onset of illness. Many cases develop within a few days, dramatically transforming an otherwise healthy individual to a patient with a high risk for developing multi-organ failure and death.
UR - http://www.scopus.com/inward/record.url?scp=0038385360&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038385360&partnerID=8YFLogxK
U2 - 10.1016/s1089-3261(03)00026-6
DO - 10.1016/s1089-3261(03)00026-6
M3 - Review article
C2 - 12879987
AN - SCOPUS:0038385360
SN - 1089-3261
VL - 7
SP - 331
EP - 349
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 2
ER -